fbpx

List – 59 Drug Patents that are Expiring in 2027

Last week we discussed the drug patents expiring in 2026. But that’s old news now. And as someone working in the generic drug market, you know how important it is to stay up to date. Right?

So, what’s new?

A drug used for the treatment of prostate cancer is going off-patent in 2027. Another one, which ministers to Type 2 Diabetes is going off-patent in the same year too. And there are so many more of them, all going off-patent in 2027!

To make your work easy, we collected not just the names of the drug patents expiring in 2027, but also included other information like the yearly sales, treatment, ingredients, and the disease they cure which could help you easily choose the drug most profitable to develop a generic version.

So, without any delay, here is the list of drugs. Thank us later!

The article has a list of drug patents expiring in 2027. You can get the drug patents expiration list from 2026 to 2030 in a PDF by filling out the form below.


Drug Patents Expiring in 2027

Procysbi
Cysteamine

More information about this Drug

Patents Expiration Date
US9925158 January 26, 2027
US9925157 January 26, 2027
US9925156 January 26, 2027

Dosage: Oral, Eye drops
Company: Horizon Therapeutics plc
Ingredients: CYSTEAMINE BITARTRATE
Treatment: Cystinosis

Ongentys
Opicapone

More information about this Drug

Patents Expiration Date
US8907099 May 12, 2027
US8168793 April 2, 2029
US9630955 December 12, 2032

Dosage: Oral
Company: Neurocrine Biosciences, Inc
Ingredients: OPICAPONE
Treatment: Parkinson’s Disease

Iclusig
Ponatinib

More information about this Drug

Patents Expiration Date
US8114874 January 24, 2027
US9493470 December 12, 2033
US11192897 December 12, 2033

Dosage: Oral
Company: Takeda Pharmaceuticals
Ingredients: PONATINIB HYDROCHLORIDE
Treatment: Chronic Myeloid Leukemia (CML) and Philadelphia chromosome-positive (Ph+), Acute Lymphoblastic Leukemia (ALL).

Ovide
Malathion

More information about this Drug

Patents Expiration Date
US7560445 February 1, 2027

Dosage: Topical
Company: Taro Pharmaceuticals
Ingredients: MALATHION
Treatment: Pediculosis

Altabax
Retapamulin

More information about this Drug

Patents Expiration Date
US7875630 February 14, 2027

Dosage: Topical
Company: GlaxoSmithKline
Ingredients: RETAPAMULIN
Treatment: Impetigo

Stribild
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil

More information about this Drug

Patents Expiration Date
US7176220 February 27, 2027
US7635704 April 26, 2027
US8981103 April 26, 2027

Dosage: Oral
Company: Gilead Sciences Inc
Ingredients: COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
Treatment: HIV/AIDS

Duavee
Conjugated Estrogens/Bazedoxifene

More information about this Drug

Patents Expiration Date
US7683051 March 10, 2027

Dosage: Oral
Company: Wyeth Pharmaceuticals Llc
Ingredients: BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED
Treatment: Hot Flashes, Osteoporosis

Zolinza
Vorinostat

More information about this Drug

Patents Expiration Date
US7456219 March 11, 2027

Dosage: Oral
Company: Merck & Co
Ingredients: VORINOSTAT
Treatment: Cutaneous T Cell Lymphoma (CTCL)

Erleada
Apalutamide

More information about this Drug

Patents Expiration Date
US9388159 March 27, 2027
US8445507 September 15, 2030
US9481663 June 4, 2033

Dosage: Oral
Company: Janssen-Cilag International NV
Ingredients: APALUTAMIDE
Treatment: Prostate Cancer

Varubi
Rolapitant

More information about this Drug

Patents Expiration Date
US8178550 April 4, 2027
US7049320 August 19, 2028

Dosage: Oral
Company: Tesaro
Ingredients: ROLAPITANT HYDROCHLORIDE
Treatment: Chemotherapy-induced Nausea And Vomiting (CINV)

Symdeko
Tezacaftor-ivacaftor

More information about this Drug

Patents Expiration Date
US10239867 April 9, 2027
US8623905 May 1, 2027
US7645789 May 1, 2027
US7776905 June 3, 2027

Dosage: Oral
Company: Vertex Pharmaceuticals Inc
Ingredients: IVACAFTOR; IVACAFTOR, TEZACAFTOR
Treatment: Cystic Fibrosis

Synjardy
Empagliflozin/Metformin

More information about this Drug

Patents Expiration Date
US7713938 April 15, 2027
US7579449 August 1, 2028

Dosage: Oral
Company: Boehringer Ingelheim/Eli Lilly And Company
Ingredients: EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Savaysa
Edoxaban

More information about this Drug

Patents Expiration Date
US7365205 April 18, 2027

Dosage: Oral
Company: Daiichi Sankyo
Ingredients: EDOXABAN TOSYLATE
Treatment: Venous Thromboembolism

Amyvid
Florbetapir (18f)

More information about this Drug

Patents Expiration Date
US8506929 April 30, 2027
US7687052 April 30, 2027

Dosage: Intravenous Injection
Company: Avid Radiopharmaceuticals
Ingredients: FLORBETAPIR F-18
Treatment: Alzheimer’s

Mekinist
Trametinib

More information about this Drug

Patents Expiration Date
US7378423 May 29, 2027

Dosage: Oral
Company: Novartis
Ingredients: TRAMETINIB DIMETHYL SULFOXIDE
Treatment: Melanoma

Altavera/Alysena/Amethyst
Ethinylestradiol/Levonorgestrel

More information about this Drug

Patents Expiration Date
US7838042 June 1, 2027

Dosage: Oral
Company: Bayer Healthcare Pharmaceuticals
Ingredients: ETHINYL ESTRADIOL; LEVONORGESTREL
Treatment: Contraception

Xadago
Safinamide

More information about this Drug

Patents Expiration Date
US8278485 June 8, 2027
US8076515 December 10, 2028

Dosage: Oral
Company: Newron Pharmaceuticals
Ingredients: SAFINAMIDE MESYLATE
Treatment: Parkinson’s Disease

Antizol
Fomepizole

More information about this Drug

Patents Expiration Date
US7553863 June 30, 2027

Dosage: Intravenous
Company: Paladin Labs
Ingredients: FOMEPIZOLE
Treatment: Ethylene Glycol And Methanol Poisoning

Vokanamet
Canagliflozin/Metformin

More information about this Drug

Patents Expiration Date
US7943788 July 14, 2027
US8513202 December 3, 2027
US7943582 February 26, 2029

Dosage: Intravenous
Company: Janssen-cilag International Nv
Ingredients: CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE
Treatment: Type 2 Diabetes

Asacol/Lialda/Pentasa
Mesalazine

More information about this Drug

Patents Expiration Date
US7645801 July 24, 2027

Dosage: Oral, Rectal
Company: Tillotts Pharma Ag.
Ingredients: MESALAMINE
Treatment: Ulcerative Colitis And Crohn’s Disease

Daklinza
Daclatasvir

More information about this Drug

Patents Expiration Date
US9421192 August 8, 2027
US8642025 August 11, 2027
US8329159 July 24, 2029
US8629171 June 13, 2031

Dosage: Oral
Company: Bristol-Myers Squibb
Ingredients: DACLATASVIR DIHYDROCHLORIDE
Treatment: Hepatitis C

Xtandi
Enzalutamide

More information about this Drug

Patents Expiration Date
US7709517 August 13, 2027

Dosage: Oral
Company: Astellas Pharma Inc.
Ingredients: ENZALUTAMIDE
Treatment: Prostate Cancer

Azilect
Rasagiline

More information about this Drug

Patents Expiration Date
US7815942 August 27, 2027

Dosage: Oral
Company: Teva Pharmaceutical
Ingredients: RASAGILINE MESYLATE
Treatment: Parkinson’s Disease

Tivicay
Dolutegravir

More information about this Drug

Patents Expiration Date
US8129385 October 5, 2027
US9242986 December 8, 2029
US10426780 January 24, 2031

Dosage: Oral
Company: Viiv Healthcare
Ingredients: DOLUTEGRAVIR SODIUM
Treatment: HIV/AIDS

Imcivree
Setmelanotide

More information about this Drug

Patents Expiration Date
US9458195 October 13, 2027
US8039435 October 13, 2027

Dosage: Subcutaneous
Company: Rhythm Pharmaceutical
Ingredients: SETMELANOTIDE ACETATE
Treatment: Genetic Obesity

Xcopri
Cenobamate

More information about this Drug

Patents Expiration Date
US7598279 October 30, 2027

Dosage: Subcutaneous
Company: SK Biopharmaceuticals
Ingredients: CENOBAMATE
Treatment: Partial Epilepsies

Pylarify
Piflufolastat F-18

More information about this Drug

Patents Expiration Date
US8487129 November 7, 2027
US9861713 July 31, 2029
US8778305 September 21, 2030
US10947197 June 9, 2037

Dosage: Intravenous
Company: Progenics Pharmaceuticals
Ingredients: PIFLUFOLASTAT F-18
Treatment: Prostate Cancer Metastasis

Korsuva
Difelikefalin

More information about this Drug

Patents Expiration Date
US10793596 November 12, 2027
US10017536 November 12, 2027
US8536131 November 12, 2027
US7727963 November 12, 2027
US7713937 November 12, 2027
US7402564 November 12, 2027

Dosage: Intravenous
Company: Cara Therapeutics
Ingredients: DIFELIKEFALIN ACETATE
Treatment: Itching

Empaveli
Pegcetacoplan

More information about this Drug

Patents Expiration Date
US9169307 November 18, 2027
US7989589 December 4, 2027
US7888323 December 4, 2027
US10125171 August 2, 2033
US10875893 November 15, 2033
US10035822 November 15, 2033

Dosage: Subcutaneous
Company: Apellis Pharmaceuticals/Swedish Orphan Biovitrum
Ingredients: PEGCETACOPLAN
Treatment: Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tabrecta
Capmatinib

More information about this Drug

Patents Expiration Date
US8461330 November 19, 2027
US7767675 November 19, 2027
US8420645 June 5, 2031
US10596178 July 22, 2035

Dosage: Subcutaneous
Company: Novartis Pharmaceuticals
Ingredients: CAPMATINIB HYDROCHLORIDE
Treatment: Non-small Cell Lung Cancer (NSCLC)

Turalio
Pexidartinib

More information about this Drug

Patents Expiration Date
US9169250 November 21, 2027
US8404700 November 21, 2027
US8722702 November 21, 2027
US7893075 October 13, 2028
US10730876 May 5, 2036
US9802932 May 5, 2036

Dosage: Subcutaneous
Company: Daiichi Sankyo Company
Ingredients: PEXIDARTINIB HYDROCHLORIDE
Treatment: Tenosynovial Giant Cell Tumor (TGCT)

Toradol/Biorolac
Ketorolac

More information about this Drug

Patents Expiration Date
US8008338 November 24, 2027
US7842714 August 15, 2029

Dosage: Oral, Intramuscular, Intravenous, Eye drops, Nasal spray
Company: Cadila Healthcare Limited
Ingredients: KETOROLAC TROMETHAMINE
Treatment: Pain

Entresto
Sacubitril/Valsartan

More information about this Drug

Patents Expiration Date
US8877938 November 27, 2027

Dosage: Oral
Company: Novartis
Ingredients: SACUBITRIL; VALSARTAN
Treatment: Heart Failure

Xermelo
Telotristat Ethyl

More information about this Drug

Patents Expiration Date
US7709493 December 11, 2027
US7553840 December 11, 2027
US8193204 February 27, 2031

Dosage: Oral
Company: Lexicon Pharmaceuticals 
Ingredients: TELOTRISTAT ETIPRATE
Treatment: Carcinoid Syndrome Diarrhea

Jakafi
Ruxolitinib

More information about this Drug

Patents Expiration Date
US8415362 December 24, 2027
US7598257 December 24, 2027
US8722693 June 12, 2028

Dosage: Oral, Topical
Company: Incyte Corp/Novartis
Ingredients: RUXOLITINIB PHOSPHATE
Treatment: Myelofibrosis

Nexavar
Sorafenib

More information about this Drug

Patents Expiration Date
US8877933 December 24, 2027

Dosage: Oral, Topical
Company: Bayer/Onyx Pharmaceuticals
Ingredients: SORAFENIB TOSYLATE
Treatment: Renal Cell Carcinoma

We know how important it is to stay a step ahead of your competitors, especially in the generic drug market. And so, our team is working on its toes to extract a list of drug patents expiring in the next 8 years from now. Want to get your hands on the list?

Get in touch

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.